<DOC>
	<DOCNO>NCT00623428</DOCNO>
	<brief_summary>This study evaluate efficacy safety peginterferon alfa-2a 40KD + ribavirin combination therapy give 24 week versus 48 week patient chronic hepatitis C , genotype 2/3 .</brief_summary>
	<brief_title>A Study Combination Therapy With PEGASYS ( Pegylated Interferon Alfa-2a ( 40KD ) ) Copegus ( Ribavirin ) Patients With Chronic Hepatitis C Genotype 2 3 Who Do Not Achieve Rapid Viral Response</brief_title>
	<detailed_description>During pre-study run-in phase patient chronic hepatitis C genotype 2/3 , start therapy PEG-IFN alfa-2a plus ribavirin accord local standard care achieve rapid viral response ( RVR ) ( define Hepatitis C virus ( HCV ) RNA &lt; 15 IU/mL Week 4 treatment measure Roche COBAS AmpliPrep / COBAS TaqManÂ® HCV Test ) eligible study enter screening phase treatment Week 4 8 soon result Week 4 HCV RNA test available . Eligible patient enter study continue dose regimen PEG-IFN alfa-2a ribavirin take prior enrolment trial Week 24 treatment . Patients achieve least 2-log10 drop HCV RNA Week 12 ( compare HCV RNA level prior treatment initiation ) HCV RNA &lt; 15 IU/mL , still take study medication treatment Week 24 , randomize treatment Week 24 one two study group . Upon randomization , participant either stop treatment ( equal 24 week treatment ) continue treatment another 24 week ( equal 48 week treatment ) . A treatment free follow-up period 24 week ( participant 48-week treatment group ) 48 week ( participant 24-week treatment group ) complete study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; serological evidence chronic hepatitis C ( CHC ) ; CHC genotype 2 3 ; receive PEGASYS + Copegus accord local standard care rapid viral response ( RVR ) ; compensate liver disease . pegylated interferon , standard interferon ribavirin therapy time prior initiation current therapy PEGASYS + Copegus ; coinfection hepatitis A B , human immunodeficiency virus ( HIV ) ; history evidence decompensated liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>